Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
(Date:7/29/2015)... SAINT-MALO, FRANCE (PRWEB) , ... July 29, 2015 ... ... , Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product ... limits the amount of sugars that are able to enter fat cells, inhibiting ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... India have demonstrated that producing nanoscopic crystals of a pharmaceutical ... gut even if the drug is not soluble in water. ... drugs being developed by the pharmaceutical industry dissolve only very ... problem for administering such drugs as it means they are ...
... InterMune, Inc. (Nasdaq: ITMN ) today ... rights to danoprevir (also known as RG7227 or ITMN-191) ... for $175 million in cash.  In connection with this ... into in October 2006 has been terminated.  In addition, ...
... SEATTLE, Oct. 6 Glencoe Software, Inc., The ... University Press are pleased to announce the release of ... first scientific image data publication system. First released in ... been under continuous development to support new image data ...
Cached Biology Technology:Nano drugs 2InterMune Sells Danoprevir Rights to Roche for $175 Million 2InterMune Sells Danoprevir Rights to Roche for $175 Million 3InterMune Sells Danoprevir Rights to Roche for $175 Million 4Glencoe Software and The Journal of Cell Biology Pioneer Online Publishing of Scientific Image Data: New Version of JCB DataViewer Released 2Glencoe Software and The Journal of Cell Biology Pioneer Online Publishing of Scientific Image Data: New Version of JCB DataViewer Released 3
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Honey is the original sweetener, manufactured by honey ... cave paintings depict honey gatherers, as do ancient Egyptian ... been important to nearly every human culture and cuisine. ... chemistry, its history, its unbelievable activity. It,s just an ...
... as environmentally conscious stand-ins for such chemicals as ... air-conditioning systems found in many large buildings. But ... suggests that this diverse class of water-treatment devices ... to flourish in the cooling systems of hospitals, ...
... lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates ... cancers, according to data presented at the 33rd Annual ... Full results were presented at the symposium during a ... CT. Reporters who cannot attend in person ...
Cached Biology News:2 books explore the history and delights of honey, bees and beehives 22 books explore the history and delights of honey, bees and beehives 32 books explore the history and delights of honey, bees and beehives 4Pitt study finds 'green' water treatments may not kill bacteria in large building cooling systems 2Combination therapy reduced HER2-positive breast cancers 2
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... years of expertise in the field of ... the most powerful systems on the market. ... 000 in-microplate tests requiring incubation and washing ... modules (such as worktable shaker incubators, reader,washer), ...
... Microsphere/Microarray Stabilizer is a is a bovine ... This product is an aqueous solution that ... (phosphate buffered saline), pH 6.6 - 7.2. ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as a ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
Biology Products: